5FD2

B-Raf wild-type kinase domain in complex with a purinylpyridinylamino-based inhibitor

Summary for 5FD2

Entry DOI	10.2210/pdb5fd2/pdb
Descriptor	Serine/threonine-protein kinase B-raf, 6-[2-[[3-(dimethylsulfamoylamino)-2,6-bis(fluoranyl)phenyl]amino]pyridin-3-yl]-7~{H}-purine (3 entities in total)
Functional Keywords	phosphotransferase, inhibitor, melanoma, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological source	Homo sapiens (Human)
Cellular location	Nucleus : P15056
Total number of polymer chains	2
Total formula weight	69944.66
Authors	Whittington, D.A.,Epstein, L.F. (deposition date: 2015-12-15, release date: 2016-05-04, Last modification date: 2024-03-06)
Primary citation	Liu, L.,Lee, M.R.,Kim, J.L.,Whittington, D.A.,Bregman, H.,Hua, Z.,Lewis, R.T.,Martin, M.W.,Nishimura, N.,Potashman, M.,Yang, K.,Yi, S.,Vaida, K.R.,Epstein, L.F.,Babij, C.,Fernando, M.,Carnahan, J.,Norman, M.H. Purinylpyridinylamino-based DFG-in/ alpha C-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling. Bioorg.Med.Chem., 24:2215-2234, 2016 Cited by PubMed: 27085672 DOI: 10.1016/j.bmc.2016.03.055 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (2.89 Å)

Structure validation